Jazz Pharmaceuticals (JAZZ) Could Be 13% Undervalued On FDA Approval Of Ziihera

Jazz Pharmaceuticals (JAZZ) is in focus after the FDA approved Ziihera-based regimens for first-line treatment of adults with unresectable locally advanced or metastatic HER2-positive gastroesophageal adenocarcinoma, supported by Phase 3 HERIZON GEA 01 data.

Jazz Pharmaceuticals’ recent FDA decision arrives after a strong run in the stock, with the share price up 41.23% year to date and a 1-year total shareholder return of 91.42%. This comes even though the 7-day share price return declined 3.83% and short term momentum has eased slightly.

Spot 19 high quality undiscovered gems that, similar to Jazz Pharmaceuticals after its Ziihera approval, pair focused drug portfolios with material late stage catalysts in under-followed corners of healthcare.

After a 91.42% 1-year total return and Ziihera’s approval, Jazz Pharmaceuticals now sits at a very different share price and business mix. Is it more sensible to step in after this move, or to wait for a cheaper entry as the valuation settles?

Most Popular Narrative: 13.1% Undervalued

Against a last close of $244.54, the most followed narrative pegs Jazz Pharmaceuticals’ fair value at $281.35, framing the recent Ziihera approval inside a broader growth story built on oncology and neuroscience expansion.

Ongoing investments in R&D, commercialization infrastructure, and international launches (such as rolling out Ziihera in BTC across Europe) are lowering barriers to entry in new geographies as healthcare access expands, which may position Jazz for steady long-term market share and revenue growth.

Read the complete narrative. Read the complete narrative.

Want to see what sits behind that higher fair value for Jazz Pharmaceuticals? The narrative focuses on compounding revenue, rising margins, and a richer future earnings multiple. Curious which specific growth paths and profitability assumptions are used to support that upgrade over the current price?

Result: Fair Value of $281.35 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, Jazz Pharmaceuticals still faces real pressure if oxybate competition bites harder than expected, or if key oncology launches and trials hit regulatory or clinical setbacks.

Find out about the key risks to this Jazz Pharmaceuticals narrative.

Next Steps

With Jazz Pharmaceuticals pulling in both concerns and optimism, it makes sense to move quickly and test the data yourself before opinions harden. To see how those red flags stack up against the upside potential, review the 3 key rewards and 2 important warning signs

Looking for more investment ideas beyond Jazz Pharmaceuticals?

Do not stop with Jazz Pharmaceuticals. Use the Simply Wall Street Screener to spot other opportunities that match your style before the crowd pays attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com